SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2019 / Cilt: 49 - Sayı: 3

Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatment

Neşe ERSÖZ GÜLÇELİK
Neşe ÇINAR
Murat TUNCEL
Firuzan Fırat ÖZER
Alper GÜRLEK
Meltem ÇAĞLAR
Kadriye AYDIN
Şafak AKIN
Aydan USMAN
Cafer BALCI
Pages
738–745
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The decrease in thyroid nodule volume with statin treatmentwas associated with neither metabolic parameters nor serum VEGF levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Defective vascularization may be important in thyroid nodular disease.
📊
Key Findings & Data:In this study, we aimed to investigate serumvascular endothelial growth factor (VEGF) levels in dyslipidemic patients with thyroid nodules, as well as the effects of statin therapy.Materials and methods: The study included 37 dyslipidemic patients with thyroid nodules and 32 dyslipidemic patients without thyroidnodules.
💡
Conclusion & Impact:The decrease in thyroid nodule volume with statin treatmentwas associated with neither metabolic parameters nor serum VEGF levels.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Defective vascularization may be important in thyroid nodular disease. In this study, we aimed to investigate serumvascular endothelial growth factor (VEGF) levels in dyslipidemic patients with thyroid nodules, as well as the effects of statin therapy.Materials and methods: The study included 37 dyslipidemic patients with thyroid nodules and 32 dyslipidemic patients without thyroidnodules. Anthropometry, serum VEGF levels, biochemical parameters, thyroid-stimulating hormone (TSH), free triiodothyronine(fT3) and free thyroxine (fT4) levels, and thyroid sonography were determined before and after 6 months of statin therapy.Results: Patients with and without thyroid nodules had similar metabolic parameters. Serum VEGF levels did not differ between thegroups. In patients with nodules, VEGF levels remained unchanged (P = 0.931) after statin therapy. However, serum VEGF levels werelowered by statin treatment in patients without nodules (P = 0.030). Statin therapy resulted in a decrease in the dominant thyroid nodulevolume. The changes in thyroid volume and dominant thyroid nodule volume were not correlated with changes in VEGF, body massindex, total cholesterol, low-density lipoprotein cholesterol, or homeostatic model assessment of insulin resistance (HOMA-IR).Conclusion: Although statin treatment decreases serum VEGF levels in dyslipidemic patients without thyroid nodules, it has nolowering effect on serum VEGF levels in patients with thyroid nodules. The decrease in thyroid nodule volume with statin treatmentwas associated with neither metabolic parameters nor serum VEGF levels.

🔖

Cite This Article

GÜLÇELİK, N. E., ÇINAR, N., TUNCEL, M., ÖZER, F. F., GÜRLEK, A., ÇAĞLAR, M., AYDIN, K., AKIN, Ş., USMAN, A., BALCI, C. (2022). Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatment. Turkish Journal of Medical Sciences, Cilt: 49 - Sayı: 3, 738–745. https://ajindex.com/articles/609978

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 2008; 18: 461-464
  2. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007; 92: 491-496
  3. Ayturk S, Gursoy A, Kut A, Anil C, Nar A, Tutuncu NB. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur J Endocrinol 2009; 161: 599-605
  4. Wang K, Yang Y, Wu Y, Chen J, Zhang D, Mao X, Wu X, Long X, Liu C. The association between insulin resistance and vascularization of thyroid nodules. J Clin Endocrinol Metab 2015; 100: 184-192
  5. Erdem H, Gundogdu C, Sipal S. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol 2011; 90: 312-317
  6. Karaca Z, Tanriverdi F, Unluhizarci K, Ozturk F, Gokahmetoglu S, Elbuken G, Cakir I, Bayram F, Kelestimur F. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 2011; 164: 277-284
  7. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL, Tuttle RM. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001; 129: 552- 558
  8. Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, Demura H, Yamaguchi S, Shibuya M. Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 1995; 96: 1295-1302
  9. Mitchell JC, Parangi S. Angiogenesis in benign and malignant thyroid disease. Thyroid 2005; 15: 494-510
  10. Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, Pierotti MA, Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999; 155: 1967-1976
  11. Tanaka K, Kurebayashi J, Sonoo H, Otsuki T, Yamamoto Y, Ohkubo S, Yamamoto S, Shimozuma K. Expression of vascular endothelial growth factor family messenger RNA in diseased thyro